Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.02 (-2.31%)
Close on Nov 18, 2026Market cap $250.67MP/E –Yield –
Ocugen free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Ocugen's free cash flow for the twelve months ending Jun 30, 2026 was -$61.02M. For fiscal 2025 it was -$57.15M. The highest annual figure on record is -$11.71M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.15M | – |
| FY2024 | Dec 31, 2024 | -$45.53M | – |
| FY2023 | Dec 31, 2023 | -$72.53M | – |
| FY2022 | Dec 31, 2022 | -$64.54M | – |
| FY2021 | Dec 31, 2021 | -$48.88M | – |
| FY2020 | Dec 31, 2020 | -$15.02M | – |
| FY2019 | Dec 31, 2019 | -$16.92M | – |
| FY2018 | Dec 31, 2018 | -$11.71M | – |
| FY2017 | Dec 31, 2017 | -$23.30M | – |
| FY2016 | Dec 31, 2016 | -$26.06M | – |
| FY2015 | Dec 31, 2015 | -$31.98M | – |
| FY2014 | Dec 31, 2014 | -$21.26M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.53M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.68M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.12M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.36M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.68M | -231.8% |
| Q4 FY2018 | Dec 31, 2018 | -$2.79M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.26M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.69M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.03M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.46M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.38M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.90M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.46M | – |
See a number that looks wrong?